Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.
DASL-HiCaP is a randomised phase 3 study aiming to demonstrate that the addition of a new oral hormonal therapy, darolutamide, to the standard radiation therapy and testosterone suppression, improves the outcomes of men with localised high-risk prostate cancer.
Primary Sponsor
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
1100
Final Accrual
1100
Trial Chairperson
Prof Christopher Sweeney and Assoc/Prof Tamim Niazi
Trial Contact
dasl.study@sydney.edu.au
Clinical Trial Registration
Related Post
26 September, 2026
Trial finds radiation therapy halves risk of brain tumour recurrence after surgery
LATEST NEWS: 26 September 2026 Giving radiotherapy after surgery
17 September, 2026
Meet the TROG Quality Assurance team
TROG UPDATES: 17 September 2026 Our Quality Assurance team